Abstract:Immunogenic cell death (ICD) is a form of apoptosis that kills susceptible populations of cancer cells while teaching the immune system to attack the remaining resistant cells. Chemotherapeutics which induce ICD elicit their immune response by inducing tumor cells to display or release damage-associated molecular patterns (DAMPs). There are two key biomarkers for ICD: 1) during the apoptotic process, tumor cells secrete ATP (extracellular ATP or eATP) and 2) during secondary necrosis, tumor cells release HMGB1 (high mobility group box 1). Because the dying tumor cells display these DAMP molecules, they stimulate the recruitment of dendritic cells (DCs) into the tumor bed and ultimately "teach" cytotoxic T-lymphocytes (CTLs) to respond to these tumor specific antigens. These primed CTLs will then kill additional tumor cells through a direct cytotoxic response. Therefore, therapeutics which provoke an ICD response offer a therapeutically desirable outcome for cancer therapy. Current assay methods such as ELISA assays and flow cytometry for measuring these ICD biomarkers are laborious and involve multiple transfer and wash steps. We have developed homogeneous (no wash), single addition assays for measuring the two principle ICD biomarkers. The eATP assay uses optimized luciferase detection chemistry that is applied directly to live cells to measure ATP release over 24 hours. The HMGB1 assay uses a complementary luciferase fragment-labeled antibody approach to measure protein concentration. We demonstrated the use of these two assays with model systems for inducing Immunogenic Cell Death with human and murine cell lines including U2OS, EL4, and U937 cells. The potency and response magnitude of ICD-inducing compounds including doxorubicin, idarubicin and mitoxantrone differs depending on the model cell line used. Further, the timing of extracellular ATP release and HMGB1 release differs between cell lines and inducers. Improved assays to measure two markers of Immunogenic Cell Death will expedite the discovery and development of inducers of Immunogenic Cell Death, including small molecule therapeutics, oncolytic viruses, radiation therapy and other novel therapeutics, by streamlining the workflow, increasing sample throughput and providing real time live cell data. Citation Format: Richard L. Somberg, Kevin Kupcho, Andrew Niles, James Cali. Detection ofHMGB1 and extracellular ATP for the assessment of immunogenic cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1112.

Cytofluorometric analysis of the maturation and activation of bone marrow-derived dendritic cells to assess immunogenic cell death

Consensus guidelines for the detection of immunogenic cell death.

Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line

eIF2α phosphorylation as a biomarker of immunogenic cell death.

The study of dendritic cells derived from acute myeloid leukemia cells]

Decoding immunogenic cell death from a dendritic cell perspective

Detection of immunogenic cell death and its relevance for cancer therapy

Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies

CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity

Abstract 1112: Detection ofHMGB1 and extracellular ATP for the assessment of immunogenic cell death

Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity

Immunogenic Cell Death in Cancer Therapy

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

Effects of Apoptotic Cells at Different Stages on Immature Dendritic Cells: Exposure to Apoptotic Cells at Late Stage Induces Maturation of Imdc Derived from Bone Marrow

Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy

Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers

Targeting immunogenic cell death in cancer

Cytotoxicity of IFN-γ-Activated Dendritic Cells to Freshly Isolated Acute Myeloid Leukemia Cells

Trial watch: chemotherapy-induced immunogenic cell death in oncology

Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.

Dismantlable Coronated Nanoparticles for Coupling the Induction and Perception of Immunogenic Cell Death